Story
Rocket Cos. Options Market Prices in 6.7% Post-Earnings Move
Summary
Traders in the options market are anticipating a potential 6.7% swing in Rocket Cos. shares following its earnings report on August 6. Historical data shows the stock's actual move has exceeded the implied volatility in half of the last eight reporting periods.
The options market is pricing in a potential 6.7% move in either direction for shares of Rocket Cos. (NYSE: RKT) following the company's upcoming earnings announcement on August 6, according to data compiled by Bloomberg.
Options Market Signals Volatility
Rocket Cos. is scheduled to release its financial results after the market closes on Tuesday, August 6. The implied move is derived from the price of options contracts and reflects traders' expectations for stock price volatility following the news, though it does not indicate the direction of the potential move.
This figure serves as a benchmark for investors, indicating how much of a price swing is currently factored into the market.
Context From Past Earnings
AdAn analysis of the past eight earnings reports shows a mixed record of the stock's actual performance compared to market expectations. The post-earnings price change has exceeded the options-implied move in exactly half of those instances, or four out of eight quarters.
Recent and notable historical moves include:
- May 7, 2026: The stock gained 9.0%, surpassing the 7.4% move priced in by options traders.
- February 26, 2026: Shares moved 1.4% lower, significantly underperforming the 10.0% implied move.
- August 1, 2024: The stock surged 17.6%, more than double the 7.1% move that had been anticipated.
- May 8, 2025: Shares fell 13.9%, a much larger drop than the 4.4% implied move.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.
Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.
Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.
J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.